ATE219672T1 - Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)- 1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen - Google Patents

Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)- 1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen

Info

Publication number
ATE219672T1
ATE219672T1 AT97907698T AT97907698T ATE219672T1 AT E219672 T1 ATE219672 T1 AT E219672T1 AT 97907698 T AT97907698 T AT 97907698T AT 97907698 T AT97907698 T AT 97907698T AT E219672 T1 ATE219672 T1 AT E219672T1
Authority
AT
Austria
Prior art keywords
dimethoxyphenyl
fluorophenyl
alpha
ethyl
treating depression
Prior art date
Application number
AT97907698T
Other languages
English (en)
Inventor
Cesare Mondadori
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE219672T1 publication Critical patent/ATE219672T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97907698T 1996-03-21 1997-02-21 Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)- 1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen ATE219672T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96400591A EP0796619A1 (de) 1996-03-21 1996-03-21 Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
PCT/US1997/002597 WO1997034603A1 (en) 1996-03-21 1997-02-21 USE OF (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL IN TREATING DEPRESSIVE DISORDERS AND BIPOLAR DISORDERS

Publications (1)

Publication Number Publication Date
ATE219672T1 true ATE219672T1 (de) 2002-07-15

Family

ID=8225234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907698T ATE219672T1 (de) 1996-03-21 1997-02-21 Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)- 1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen

Country Status (22)

Country Link
US (2) US6022877A (de)
EP (2) EP0796619A1 (de)
JP (1) JP4165906B2 (de)
KR (1) KR100423018B1 (de)
CN (1) CN1114406C (de)
AR (1) AR006281A1 (de)
AT (1) ATE219672T1 (de)
AU (1) AU704435B2 (de)
BR (1) BR9708109A (de)
CA (1) CA2250077C (de)
DE (1) DE69713571T2 (de)
DK (1) DK0888114T3 (de)
ES (1) ES2175356T3 (de)
HU (1) HU226675B1 (de)
IL (1) IL126022A (de)
NO (2) NO316788B1 (de)
NZ (1) NZ331448A (de)
PT (1) PT888114E (de)
SI (1) SI0888114T1 (de)
TW (1) TW517048B (de)
WO (1) WO1997034603A1 (de)
ZA (1) ZA972345B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
KR100682799B1 (ko) * 1998-08-28 2007-02-15 아벤티스 파마슈티칼스 인크. Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물
US20020099076A1 (en) 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
ES2248231T3 (es) * 2001-01-31 2006-03-16 Pfizer Products Inc. Derivados de eteres utiles como inhibidores de las isozimas pde4.
EP2305645B1 (de) 2008-06-20 2012-05-16 NHWA Pharma.corporation Aralkylpiperidinderivate und ihre verwendungen als schmerz- oder beruhigungsmittel
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
HUP9903684A3 (en) * 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen

Also Published As

Publication number Publication date
AU704435B2 (en) 1999-04-22
CN1114406C (zh) 2003-07-16
EP0888114B1 (de) 2002-06-26
CA2250077A1 (en) 1997-09-25
CN1213968A (zh) 1999-04-14
NO20033184L (no) 1998-09-18
IL126022A0 (en) 1999-05-09
NO984348L (no) 1998-09-18
ZA972345B (en) 1997-09-25
PT888114E (pt) 2002-11-29
US6380216B1 (en) 2002-04-30
AU1963197A (en) 1997-10-10
HUP9902135A3 (en) 2001-05-28
IL126022A (en) 2003-11-23
NO984348D0 (no) 1998-09-18
US6022877A (en) 2000-02-08
HK1019702A1 (en) 2000-02-25
BR9708109A (pt) 1999-07-27
WO1997034603A1 (en) 1997-09-25
DE69713571D1 (de) 2002-08-01
SI0888114T1 (en) 2002-10-31
KR20000064711A (ko) 2000-11-06
EP0888114A1 (de) 1999-01-07
NO316788B1 (no) 2004-05-10
TW517048B (en) 2003-01-11
DK0888114T3 (da) 2002-10-07
DE69713571T2 (de) 2003-02-20
JP4165906B2 (ja) 2008-10-15
ES2175356T3 (es) 2002-11-16
NZ331448A (en) 2000-06-23
AR006281A1 (es) 1999-08-11
KR100423018B1 (ko) 2004-05-17
HUP9902135A2 (hu) 1999-11-29
HU226675B1 (en) 2009-06-29
CA2250077C (en) 2003-10-07
EP0796619A1 (de) 1997-09-24
JP2000506887A (ja) 2000-06-06
NO20033184D0 (no) 2003-07-11

Similar Documents

Publication Publication Date Title
ATE300597T1 (de) Behandlung von geweben
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE69815313D1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
ATE219672T1 (de) Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)- 1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
ATE303817T1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69721756D1 (de) Paroxetine zur behandlung von depression
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
EP0909172A4 (de) Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat
DE69814993D1 (de) Quasi-azeotrope Mischungen auf Basis von 1,1,1,3,3,-Pentafluorobutan, Methylene Chloride und Methanol zur Behandlung von festen Oberflächen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee